Skip to main content Accessibility help
×
Hostname: page-component-78c5997874-g7gxr Total loading time: 0 Render date: 2024-11-10T20:31:36.816Z Has data issue: false hasContentIssue false

28 - Heme Biosynthesis and the Porphyrias

from SECTION IV - METABOLIC LIVER DISEASE

Published online by Cambridge University Press:  18 December 2009

Robert J. Desnick M.D., Ph.D.
Affiliation:
Professor and Chairman, Departments of Genetics and Genomic Science and Pediatrics, Mount Sinai School of Medicine of New York University, New York, New York; Attending Physician, Department of Pediatrics, Mount Sinai Hospital, New York, New York
Kenneth H. Astrin Ph.D.
Affiliation:
Associate Professor, Department of Genetics and Genomic Sciences, Mount Sinai School of Medicine of New York University, New York, New York
Karl E. Anderson M.D.
Affiliation:
Professor of Medicine, Department of Preventive Medicine and Community Health, University of Texas Medical Branch, Galveston, Texas
Frederick J. Suchy
Affiliation:
Mount Sinai School of Medicine, New York
Ronald J. Sokol
Affiliation:
University of Colorado, Denver
William F. Balistreri
Affiliation:
University of Cincinnati
Get access

Summary

The porphyrias are metabolic disorders, each resulting from the deficiency of a specific enzyme in the heme biosynthetic pathway (Figure 28.1; Table 28.1). These enzyme deficiencies are inherited as autosomal dominant or recessive traits, with the exception of porphyria cutanea tarda (PCT), which usually is sporadic. The porphyrias are classified as either hepatic or erythropoietic depending on the primary site of overproduction and accumulation of porphyrin precursors or porphyrins (Table 28.2) although some have overlapping features. The hepatic porphyrias are characterized by overproduction and initial accumulation of porphyrin precursors and/or porphyrins primarily in the liver, whereas in the erythropoietic porphyrias, overproduction and initial accumulation of the pathway intermediates occur primarily in bone marrow erythroid cells.

The major manifestations of the acute hepatic porphyrias, which typically present after puberty, are neurologic, including neuropathic abdominal pain, neuropathy, and mental disturbances. The neurologic involvement appears to be the result of hepatic production of a neurotoxic substance, as liver transplantation prevented further occurrences in a patient who had frequent attacks of acute intermittent porphyria (AIP) [1]. Steroid hormones, drugs, and nutrition influence the hepatic production of porphyrin precursors and porphyrins, thereby precipitating or increasing the severity of some hepatic porphyrias. Rare homozygous variants of the autosomal dominant hepatic porphyrias have been identified and usually manifest clinically before puberty. The symptoms in these patients are usually more severe and occur earlier than those of patients with the respective autosomal dominant porphyria (see below) [2].

Type
Chapter
Information
Publisher: Cambridge University Press
Print publication year: 2007

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Soonawalla, Z F, Orug, T, Badminton, M N. Liver transplantation as a cure for acute intermittent porphyria. Lancet 2004;363:705–6.CrossRefGoogle ScholarPubMed
Elder, G H. Hepatic porphyrias in children. J Inherit Metab Dis 1997;20:237–46.CrossRefGoogle ScholarPubMed
Anderson KE, Sassa S, Bishop DF, et al. Disorders of heme biosynthesis: X-linked sideroblastic anemias and the porphyrias, In: Scriver, C R, Beaudet, A L, Sly, W S., eds. The metabolic and molecular basis of inherited disease. New York: McGraw-Hill, 2001:2991–3062.Google Scholar
Desnick, R J, Astrin, K H. Congenital erythropoietic porphyria: advances in pathogenesis and treatment. Br J Haematol 2002;117:779–95.CrossRefGoogle ScholarPubMed
Anderson, K E, Bloomer, J E, Bonkovsky, H L. Recommendations for the diagnosis and treatment of the acute porphyrias. Ann Intern Med 2005;142:439–51.CrossRefGoogle ScholarPubMed
Desnick, R J, Anderson, K E, Astrin, K H. Inherited porphyrias. In: Rimoin, D L, Conner, J M, Pyeritz, R E. Emery and Rimoin's principles and practice of medical genetics. Edinburgh: Churchill Livingstone, 2002;2586–623.Google Scholar
Badminton, M N, Elder, G H. Molecular mechanisms of dominant expression in porphyria. J Inherit Metab Dis 2005;28:277–86.CrossRefGoogle ScholarPubMed
Kauppinen, R. Porphyrias. Lancet 2005;365:241–52.CrossRefGoogle ScholarPubMed
May, B K, Dogra, S C, Sadlon, T J. Molecular regulation of heme biosynthesis in higher vertebrates. Prog Nucleic Acid Res Mol Biol 1995;51:1–51.CrossRefGoogle ScholarPubMed
Kaya, A H, Plewinska, M, Wong, D M. Human δ-aminolevulinate dehydratase (ALAD) gene: structure and alternative splicing of the erythroid and housekeeping mRNAs. Genomics 1994;19:242–8.CrossRefGoogle ScholarPubMed
Grandchamp, B, Verneuil, H, Beaumont, C. Tissue specific expression of porphobilinogen deaminase. Two isoenzymes from a single gene. Eur J Biochem 1987;162:105–10.CrossRefGoogle ScholarPubMed
Aizencang, G, Solis, C, Bishop, D F. Human uroporphyrinogen-III synthase: genomic organization, alternative promoters, and erythroid-specific expression. Genomics 2000;70:223–31.CrossRefGoogle ScholarPubMed
Sassa, S. ALAD porphyria. Semin Liver Dis 1998;18:95–101.CrossRefGoogle ScholarPubMed
Doss, M O, Stauch, T, Gross, U. The third case of Doss porphyria (delta-amino-levulinic acid dehydratase deficiency) in Germany. J Inherit Metab Dis 2004;27:529–36.CrossRefGoogle Scholar
Akagi, R, Kato, N, Inoue, R. delta-Aminolevulinate dehydratase (ALAD) porphyria: the first case in North America with two novel ALAD mutations. Mol Genet Metab 2006;87:329–36.CrossRefGoogle ScholarPubMed
Maruno, M, Furuyama, K, Akagi, R. Highly heterogeneous nature of delta-aminolevulinate dehydratase (ALAD) deficiencies in ALAD porphyria. Blood 2001;97:2972–8.CrossRefGoogle ScholarPubMed
Sassa, S, Akagi, R, Nishitani, C. Late-onset porphyrias: what are they?Cell Mol Biol (Noisy-le-grand) 2002;48:97–101.Google Scholar
Stenson, P D, Ball, E V, Mort, M. Human Gene Mutation Database (HGMD): 2003 update. Hum Mutat 2003;21:577–81.CrossRefGoogle ScholarPubMed
Plewinska, M, Thunell, S, Holmberg, L. δ-Aminolevulinate dehydratase deficient porphyria: identification of the molecular lesions in a severely affected homozygote. Am J Hum Genet 1991;49:167–74.Google Scholar
Astrin, K H, Bishop, D F, Wetmur, J G. delta-Aminolevulinic acid dehydratase isozymes and lead toxicity. Ann N Y Acad Sci 1987;514:23–9.CrossRefGoogle ScholarPubMed
Handschin, C, Lin, J, Rhee, J. Nutritional regulation of hepatic heme biosynthesis and porphyria through PGC-1alpha. Cell 2005;122:505–15.CrossRefGoogle ScholarPubMed
Grandchamp, B, Picat, C, Mignotte, V. Tissue-specific splicing mutation in acute intermittent porphyria. Proc Nat Acad Sci U S A 1989;86:661–4.CrossRefGoogle ScholarPubMed
Llewellyn, D H, Smyth, S J, Elder, G H. Homozygous acute intermittent porphyria: compound heterozygosity for adjacent base transitions in the same codon of the porphobilinogen deaminase gene. Hum Genet 1992;89:97–8.CrossRefGoogle ScholarPubMed
Solis, C, Martinez-Bermejo, A, Naidich, T P. Acute intermittent porphyria: studies of the severe homozygous dominant disease provides insights into the neurologic attacks in acute porphyrias. Arch Neurol 2004;61:1764–70.CrossRefGoogle ScholarPubMed
Elder, G H. Porphyria cutanea tarda. Semin Liver Dis 1998;18:67–75.CrossRefGoogle ScholarPubMed
Thunell, S, Harper, P. Porphyrins, porphyrin metabolism, porphyrias. III. Diagnosis, care and monitoring in porphyria cutanea tarda – suggestions for a handling programme. Scand J Clin Lab Invest 2000;60:561–79.Google ScholarPubMed
Elder, G H. Porphyria cutanea tarda and related disorders. In: Kadish, K M, Smith, K, Guilard, R. Porphyrin handbook, part II. San Diego: Academic Press, 2003:67–92.Google Scholar
Bonkovsky, H L, Poh-Fitzpatrick, M, Pimstone, N. Porphyria cutanea tarda, hepatitis C, and HFE gene mutations in North America. Hepatology 1998;27:1661–9.CrossRefGoogle ScholarPubMed
Mehrany, K, Drage, L A, Brandhagen, D J. Association of porphyria cutanea tarda with hereditary hemochromatosis. J Am Acad Dermatol 2004;51:205–11.CrossRefGoogle ScholarPubMed
Egger, N G, Goeger, D E, Payne, D A. Porphyria cutanea tarda: multiplicity of risk factors including HFE mutations, hepatitis C, and inherited uroporphyrinogen decarboxylase deficiency. Dig Dis Sci 2002;47:419–26.CrossRefGoogle ScholarPubMed
Bonkovsky, H L, Barnard, G F. Diagnosis of porphyric syndromes: a practical approach in the era of molecular biology. Semin Liver Dis 1998;18:57–65.CrossRefGoogle ScholarPubMed
Anderson, K E. The porphyrias. In: Goldman, L, Bennett, C J. Cecil textbook of medicine. Philadelphia: WB Saunders, 2000:1123–32.Google Scholar
Kuhnel, A, Gross, U, Doss, M O. Hereditary coproporphyria in Germany: clinical-biochemical studies in 53 patients. Clin Biochem 2000;33:465–73.CrossRefGoogle ScholarPubMed
Martasek, P. Hereditary coproporphyria. Semin Liver Dis 1998;18:25–32.CrossRefGoogle ScholarPubMed
Martasek, P, Nordmann, Y, Grandchamp, B. Homozygous hereditary coproporphyria caused by an arginine to tryptophane substitution in coproporphyrinogen oxidase and common intragenic polymorphisms. Hum Mol Genet 1994;3:477–80.CrossRefGoogle ScholarPubMed
Nordmann, Y, Grandchamp, B, Verneuil, H. Harderoporphyria: a variant hereditary coproporphyria. J Clin Invest 1983;72:1139–49.CrossRefGoogle ScholarPubMed
Lee, D S, Flachsova, E, Bodnarova, M. Structural basis of hereditary coproporphyria. Proc Natl Acad Sci U S A 2005;102: 14232–7.CrossRefGoogle ScholarPubMed
Schmitt, C, Gouya, L, Malonova, E. Mutations in human CPO gene predict clinical expression of either hepatic hereditary coproporphyria or erythropoietic harderoporphyria. Hum Mol Genet 2005;14:3089–98.CrossRefGoogle ScholarPubMed
Meissner P, Hift RJ, Corrigall A. Variegate porphyria. In: Kadish, K M, Smith, K, Guilard, R, eds. Porphyrin handbook, part II. San Diego: Academic Press, 2003:93–120.Google Scholar
Poh-Fitzpatrick, M B. A plasma porphyrin fluorescence marker for variegate porphyria. Arch Dermatol 1980;116:543–7.CrossRefGoogle ScholarPubMed
Meissner, P N, Dailey, T A, Hift, R J. A R59W mutation in human protoporphyrinogen oxidase results in decreased enzyme activity and is prevalent in South Africans with variegate porphyria. Nat Genet 1996;13:95–7.CrossRefGoogle Scholar
Whatley, S D, Puy, H, Morgan, R R. Variegate porphyria in Western Europe: identification of PPOX gene mutations in 104 families, extent of allelic heterogeneity, and absence of correlation between phenotype and type of mutation. Am J Hum Genet 1999;65:984–94.CrossRefGoogle ScholarPubMed
Roberts, A G, Puy, H, Dailey, T A. Molecular characterization of homozygous variegate porphyria. Hum Mol Genet 1998;7:1921–5.CrossRefGoogle ScholarPubMed
Palmer, R A, Elder, G H, Barrett, D F. Homozygous variegate porphyria: a compound heterozygote with novel mutations in the protoporphyrinogen oxidase gene. Br J Dermatol 2001;144:866–9.CrossRefGoogle ScholarPubMed
Kauppinen, R, Timonen, K, und zu Fraunberg, M. Homozygous variegate porphyria: 20 y follow-up and characterization of molecular defect. J Invest Dermatol 2001;116:610–13.CrossRefGoogle Scholar
Solis, C, Aizencang, G I, Astrin, K H. Uroporphyrinogen III synthase erythroid promoter mutations in adjacent GATA1 and CP2 elements cause congenital erythropoietic porphyria. J Clin Invest 2001;107:753–62.CrossRefGoogle ScholarPubMed
Piomelli, S, Poh-Fitzpatrick, M B, Seaman, C. Complete suppression of the symptoms of congenital erythropoietic porphyria by long-term treatment with high-level transfusions. N Engl J Med 1986;314:1029–31.CrossRefGoogle ScholarPubMed
Dupuis-Girod, S, Akkari, V, Ged, C. Successful match-unrelated donor bone marrow transplantation for congenital erythropoietic porphyria (Gunther disease). Eur J Pediatr 2005;164:104–7.CrossRefGoogle Scholar
Shaw, P H, Mancini, A J, McConnell, J P. Treatment of congenital erythropoietic porphyria in children by allogeneic stem cell transplantation: a case report and review of the literature. Bone Marrow Transplant 2001;27:101–5.CrossRefGoogle ScholarPubMed
Mazurier, F, Geronimi, F, Lamrissi-Garcia, I. Correction of deficient cd34(+) cells from peripheral blood after mobilization in a patient with congenital erythropoietic porphyria. Mol Ther 2001;3:411–17.CrossRefGoogle Scholar
Cox, T M, Alexander, G J, Sarkany, R P. Protoporphyria. Semin Liver Dis 1998;18:85–93.CrossRefGoogle ScholarPubMed
Cox, T M. Protoporphyria. In: Kadish, K M, Smith, K, Guilard, R. Porphyrin handbook, part II. San Diego: Academic Press, 2003:121–49.Google Scholar
Gouya, L, Puy, H, Robreau, A M. The penetrance of dominant erythropoietic protoporphyria is modulated by expression of wildtype FECH. Nat Genet 2002;30:27–8.CrossRefGoogle ScholarPubMed
Gouya, L, Martin-Schmitt, C, Robreau, A M. Contribution of a common single-nucleotide polymorphism to the genetic predisposition for erythropoietic protoporphyria. Am J Hum Genet 2006;78:2–14.CrossRefGoogle ScholarPubMed
Risheg, H, Chen, F P, Bloomer, J R. Genotypic determinants of phenotype in North American patients with erythropoietic protoporphyria. Mol Genet Metab 2003;80:196–206.CrossRefGoogle ScholarPubMed
Bloomer, J, Wang, Y, Singhal, A. Molecular studies of liver disease in erythropoietic protoporphyria. J Clin Gastroenterol 2005;39:S167–75.CrossRefGoogle ScholarPubMed
Najahi-Missaoui, W, Dailey, H A. Production and characterization of erythropoietic protoporphyric heterodimeric ferrochelatases. Blood 2005;106:1098–104.CrossRefGoogle ScholarPubMed
Ohgari, Y, Sawamoto, M, Yamamoto, M. Ferrochelatase consisting of wild-type and mutated subunits from patients with a dominant-inherited disease, erythropoietic protoporphyria, is an active but unstable dimer. Hum Mol Genet 2005;14:327–34.CrossRefGoogle ScholarPubMed
Wilson, J, Edixhoven-Bosdijk, A, Koole-Lesuis, R. A new variant of erythropoietic protoporphyria with normal ferrochelatase activity. Physiol Res 2003;52:29S.Google Scholar
Meerman, L, Koopen, N R, Bloks, V. Biliary fibrosis associated with altered bile composition in a mouse model of erythropoietic protoporphyria. Gastroenterology 1999;117:696–705.CrossRefGoogle Scholar
Rank, J F, Carithers, R, Bloomer, J. Evidence for neurological dysfunction in end-stage protoporphyric liver disease. Hepatology 1993;18:1404–9.CrossRefGoogle ScholarPubMed
Minder, E I, Gouya, L, Schneider-Yin, X. A genotype-phenotype correlation between null-allele mutations in the ferrochelatase gene and liver complication in patients with erythropoietic protoporphyria. Cell Mol Biol (Noisy-le-grand) 2002;48:91–6.Google ScholarPubMed
McGuire, B M, Bonkovsky, H L, Carithers, R L. Liver transplantation for erythropoietic protoporphyria liver disease. Liver Transpl 2005;11:1590–6.CrossRefGoogle ScholarPubMed
Poh-Fitzpatrick, M B, Wang, X, Anderson, K E. Erythropoietic protoporphyria: altered phenotype after bone marrow transplantation for myelogenous leukemia in a patient heteroallelic for ferrochelatase gene mutations. J Amer Acad Dermatol 2002;46:861–6.CrossRefGoogle Scholar
Fontanellas, A, Mazurier, F, Landry, M. Reversion of hepatobiliary alterations by bone marrow transplantation in a murine model of erythropoietic protoporphyria. Hepatology 2000;32:73–81.CrossRefGoogle Scholar
Whatley, S D, Mason, N G, Khan, M. Autosomal recessive erythropoietic protoporphyria in the United Kingdom: prevalence and relationship to liver disease. J Med Genet 2004;41: e105.CrossRefGoogle ScholarPubMed
Day, R S, Eales, L, Meissner, D. Coexistent variegate porphyria and porphyria cutanea tarda. N Engl J Med 1982;30:36–41.CrossRefGoogle Scholar
Nordmann, Y, Amram, D, Deybach, J C. Coexistent hereditary coproporphyria and congenital erythropoietic porphyria (Günther disease). J Inherited Metab Dis 1990;13:687–91.CrossRefGoogle Scholar
Freesemann, A G, Hofweber, K, Doss, M O. Coexistence of deficiencies of uroporphyrinogen III synthase and decarboxylase in a patient with congenital erythropoietic porphyria and in his family. Eur J Clin Chem Clin Biochem 1997;35:35–9.Google Scholar
Weinlich, G, Doss, M O, Sepp, N. Variegate porphyria with coexistent decrease in porphobilinogen deaminase activity. Acta Derm Venereol 2001;81:356–9.CrossRefGoogle ScholarPubMed
Doss, M O, Gross, U, Puy, H. [Coexistence of hereditary coproporphyria and porphyria cutanea tarda: a new form of dual porphyria]. Med Klin 2002;97:1–5.CrossRefGoogle Scholar
Akagi, R, Inoue, R, Muranaka, S. Dual gene defects involving delta-aminolaevulinate dehydratase and coproporphyrinogen oxidase in a porphyria patient. Br J Haematol 2006;132:237–43.CrossRefGoogle Scholar
Harraway, J R, Florkowski, C M, Sies, C. Dual porphyria with mutations in both the UROD and HMBS genes. Ann Clin Biochem 2006;43:80–2.CrossRefGoogle ScholarPubMed
Lindberg, R L, Porcher, C, Grandchamp, B. Porphobilinogen deaminase deficiency in mice causes a neuropathy resembling that of human hepatic porphyria. Nat Genet 1996;12:195–9.CrossRefGoogle ScholarPubMed
Bensidhoum, M, Audine, M, Fontanellas, A. The disruption of mouse uroporphyrinogen III synthase (uros) gene is fully lethal. Acta Haematologica 1997;98(suppl 1):100.Google Scholar
Magness, S T, Brenner, D A. Targeted disruption of the mouse ferrochelatase gene producing an exon 10 deletion. Biochim Biophys Acta 1999;1453:161–74.CrossRefGoogle ScholarPubMed
Bishop, D F, Johansson, A, Phelps, R. Uroporphyrinogen III synthase knock-in mice have the human congenital erythropoietic porphyria phenotype, including the characteristic light-induced cutaneous lesions. Am J Hum Genet 2006;78:645–58.CrossRefGoogle ScholarPubMed
Ged, C, Mendez, M, Robert, E. A knock-in mouse model of congenital erythropoietic porphyria. Genomics 2006;87:84–92.CrossRefGoogle ScholarPubMed
Phillips, J D, Jackson, L K, Bunting, M. A mouse model of familial porphyria cutanea tarda. Proc Natl Acad Sci U S A 2001;98:259–64.CrossRefGoogle ScholarPubMed
Sinclair, P R, Gorman, N, Trask, H W. Uroporphyria caused by ethanol in Hfe(-/-) mice as a model for porphyria cutanea tarda. Hepatology 2003;37:351–8.CrossRefGoogle ScholarPubMed
Medlock, A E, Meissner, P N, Davidson, B P. A mouse model for South African (R59W) variegate porphyria: construction and initial characterization. Cell Mol Biol (Noisy-le-grand) 2002;48:71–8.Google ScholarPubMed
Tutois, S, Montagutelli, X, Dasilva, V. Erythropoietic protoporphyria in the house mouse: a recessive inherited ferrochelatase deficiency with anemia, photosensitivity, and liver disease. J Clin Invest 1991;88:1730–6.CrossRefGoogle ScholarPubMed
Lindberg, R L, Martini, R, Baumgartner, M. Motor neuropathy in porphobilinogen deaminase-deficient mice imitates the peripheral neuropathy of human acute porphyria. J Clin Invest 1999;103:1127–34.CrossRefGoogle ScholarPubMed
Meyer, U A, Schuurmans, M M, Lindberg, R L P. Acute porphyrias: pathogenesis of neurological manifestations. Semin Liver Dis 1998;18:43–52.CrossRefGoogle ScholarPubMed
Magness, S T, Maeda, N, Brenner, D A. An exon 10 deletion in the mouse ferrochelatase gene has a dominant-negative effect and causes mild protoporphyria. Blood 2002;100:1470–7.CrossRefGoogle Scholar

Save book to Kindle

To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

  • Heme Biosynthesis and the Porphyrias
    • By Robert J. Desnick, M.D., Ph.D., Professor and Chairman, Departments of Genetics and Genomic Science and Pediatrics, Mount Sinai School of Medicine of New York University, New York, New York; Attending Physician, Department of Pediatrics, Mount Sinai Hospital, New York, New York, Kenneth H. Astrin, Ph.D., Associate Professor, Department of Genetics and Genomic Sciences, Mount Sinai School of Medicine of New York University, New York, New York, Karl E. Anderson, M.D., Professor of Medicine, Department of Preventive Medicine and Community Health, University of Texas Medical Branch, Galveston, Texas
  • Edited by Frederick J. Suchy, Mount Sinai School of Medicine, New York, Ronald J. Sokol, University of Colorado, Denver, William F. Balistreri, University of Cincinnati
  • Book: Liver Disease in Children
  • Online publication: 18 December 2009
  • Chapter DOI: https://doi.org/10.1017/CBO9780511547409.030
Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

  • Heme Biosynthesis and the Porphyrias
    • By Robert J. Desnick, M.D., Ph.D., Professor and Chairman, Departments of Genetics and Genomic Science and Pediatrics, Mount Sinai School of Medicine of New York University, New York, New York; Attending Physician, Department of Pediatrics, Mount Sinai Hospital, New York, New York, Kenneth H. Astrin, Ph.D., Associate Professor, Department of Genetics and Genomic Sciences, Mount Sinai School of Medicine of New York University, New York, New York, Karl E. Anderson, M.D., Professor of Medicine, Department of Preventive Medicine and Community Health, University of Texas Medical Branch, Galveston, Texas
  • Edited by Frederick J. Suchy, Mount Sinai School of Medicine, New York, Ronald J. Sokol, University of Colorado, Denver, William F. Balistreri, University of Cincinnati
  • Book: Liver Disease in Children
  • Online publication: 18 December 2009
  • Chapter DOI: https://doi.org/10.1017/CBO9780511547409.030
Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

  • Heme Biosynthesis and the Porphyrias
    • By Robert J. Desnick, M.D., Ph.D., Professor and Chairman, Departments of Genetics and Genomic Science and Pediatrics, Mount Sinai School of Medicine of New York University, New York, New York; Attending Physician, Department of Pediatrics, Mount Sinai Hospital, New York, New York, Kenneth H. Astrin, Ph.D., Associate Professor, Department of Genetics and Genomic Sciences, Mount Sinai School of Medicine of New York University, New York, New York, Karl E. Anderson, M.D., Professor of Medicine, Department of Preventive Medicine and Community Health, University of Texas Medical Branch, Galveston, Texas
  • Edited by Frederick J. Suchy, Mount Sinai School of Medicine, New York, Ronald J. Sokol, University of Colorado, Denver, William F. Balistreri, University of Cincinnati
  • Book: Liver Disease in Children
  • Online publication: 18 December 2009
  • Chapter DOI: https://doi.org/10.1017/CBO9780511547409.030
Available formats
×